• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $GEHC alert in real time by email

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.

    Logo for PharmaLogic Holdings Corporation.

    Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across global markets. Prior to joining PharmaLogic one year ago, he held executive positions at Lantheus (NASDAQ:LNTH), GE HealthCare (NASDAQ:GEHC) and Ipsen (EURONEXT: IPN).

    Steve Chilinski, who has led the company through 13 years of exceptional growth, retired as Chief Executive Officer on June 1, 2025, and will assume the role of Executive Chairman of the Board.

    "I'm grateful to Steve and the Board for their trust and their confidence in PharmaLogic's future," said Etienne Montagut. "The company has experienced great success, and I'm very excited about our next chapter. PharmaLogic has talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to novel diagnostics and therapies."

    About PharmaLogic Holdings Corp.

    PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specialized in diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a robust network of more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards.

    Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and Alzheimer's disease. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic across more than 30 countries.

    PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit radiopharmacy.com and follow us on LinkedIn.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmalogic-announces-appointment-of-etienne-montagut-as-president-and-chief-executive-officer-302470235.html

    SOURCE PharmaLogic Holdings Corp

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC
    $LNTH

    CompanyDatePrice TargetRatingAnalyst
    Lantheus Holdings Inc.
    $LNTH
    8/12/2025$63.00Buy → Hold
    Truist
    GE HealthCare Technologies Inc.
    $GEHC
    5/5/2025$73.00Sell → Neutral
    UBS
    GE HealthCare Technologies Inc.
    $GEHC
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    Lantheus Holdings Inc.
    $LNTH
    12/18/2024$143.00Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    GE HealthCare Technologies Inc.
    $GEHC
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    GE HealthCare Technologies Inc.
    $GEHC
    9/9/2024$90.00Neutral
    JP Morgan
    More analyst ratings

    $GEHC
    $LNTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    8/14/25 11:17:17 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SCHEDULE 13G filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

    8/13/25 4:35:15 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 144 filed by Lantheus Holdings Inc.

    144 - Lantheus Holdings, Inc. (0001521036) (Subject)

    8/13/25 12:48:42 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $GEHC
    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare Enters an Agreement to Distribute Flyrcado Through CDL Nuclear Technologies Group, a Leading Provider of Cardiac PET Imaging Equipment and Services in the U.S.

    GE HealthCare's agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado. Through their nearly 225 U.S. customers, CDL and CardioNavix support more than 220,000 cardiac PET procedures annually. This agreement builds the capabilities needed to support Flyrcado's growth in outpatient cardiac PET imaging by pairing CardioNavix's comprehensive program setup, workflow, and clinical and operations support with GE HealthCare's contract manufacturing organization (CMO) network to accelerate site enablement. GE HealthCare (NASDAQ:GEHC) today announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the

    9/8/25 9:14:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

    BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9. To access the live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lantheus

    9/2/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    GE HealthCare unveils Vivid Pioneer, its most advanced AI-powered cardiovascular ultrasound system, designed to enhance speed and image quality for improved diagnostic confidence and workflow efficiency

    GE HealthCare (NASDAQ:GEHC) today announced the launch of the Vivid™ Pioneer, its most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet, completely redesigned to support clinicians with extraordinary imaging in 2D, 4D and color flow, streamlined workflow, and enhanced diagnostic confidence. The ultrasound system recently received CE Mark and U.S. FDA 510(k) clearance. Cardiovascular diseases (CVDs) remain the leading cause of death in the world, accounting for nearly a third of all global deaths.i Reducing the burden of these diseases can be challenging, as their progression often goes unnoticed due to the asymptomatic nature of many CVDs in the early stages.ii Ea

    8/29/25 7:45:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

    3/8/24 11:24:53 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $GEHC
    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Marshall Robert J. Jr. covered exercise/tax liability with 727 shares, decreasing direct ownership by 0.82% to 88,133 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    9/3/25 4:29:54 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Enterprise Oper. Officer Stacherski Kenneth R. covered exercise/tax liability with 892 shares, decreasing direct ownership by 2% to 40,996 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:19:36 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief People Officer Holton Adam Y covered exercise/tax liability with 464 shares, decreasing direct ownership by 3% to 16,768 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:18:39 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings downgraded by Truist with a new price target

    Truist downgraded Lantheus Holdings from Buy to Hold and set a new price target of $63.00

    8/12/25 7:56:11 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    GE HealthCare upgraded by UBS with a new price target

    UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

    5/5/25 8:34:55 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Goldman with a new price target

    Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

    3/11/25 7:35:30 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

    BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

    7/22/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    $LNTH
    Financials

    Live finance-specific insights

    View All

    Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

    Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease; FDA label expansion for Neuraceq in JuneBoard of Directors authorized a program to repurchase up to $400

    8/6/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    GE HealthCare reports second quarter 2025 financial results

    Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was $7 million versus $(182) million Raises full-year 2025 guidance GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We were pleas

    7/30/25 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    7/23/25 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $GEHC
    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

    SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 3:29:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care